News and reporting on cancer immunotherapy.
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.
The diagnostic can now be used to identify patients with head and neck squamous cell carcinoma who may benefit from first-line treatment with Keytruda.
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.